Management of metastatic gastrointestinal stromal tumour in the Glivec era: A practical case-based approach

Internal Medicine Journal

Volumn 36, Issue 6, 2006, Pages 367-377

  Harrison, M L ^a   Goldstein, D ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Gastrointestinal stromal tumour; Imatinib; Metastatic cancer; Surgery; Toxicity

Indexed keywords

AMINOTRANSFERASE; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ATROPINE PLUS DIPHENOXYLATE; DIPHENOXYLATE; ERYTHROPOIETIN; IMATINIB; LOPERAMIDE; METOCLOPRAMIDE; STEM CELL FACTOR RECEPTOR; STEROID; SUNITINIB;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; AUSTRALIA; BLEEDING; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FACE RASH; FATIGUE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INTERSTITIAL PNEUMONIA; LETHARGY; LIVER DYSFUNCTION; LIVER METASTASIS; LIVER TOXICITY; MACULOPAPULAR RASH; METASTASIS; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PLEURAL PAIN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; PRURITUS; RECTUM HEMORRHAGE; REVIEW; SWEDEN; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR DIAGNOSIS; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 33646874774     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2006.01077.x     Document Type: Review

References (43)

1. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumour (GIPACT): gastrointestinal stromal tumours show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998 152 : 1259 69.
2. Rubin BP, Fletcher JA, Fletcher CDM. Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumours. Int J Surg Pathol 2000 8 : 5 10.
3. Robinson TL, Sircar K, Hewlett BR, Chorneyko K, Riddell RH, Huizinga JD. Gastrointestinal stromal tumours may originate from a subset of CD34-positive interstitial cells of Cajal. Am J Pathol 2000 156 : 1157 63.
4. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours. Science 1998 279 : 577 80.
5. DeMatteo RP, Heinrich MC, El-Rifai W, Demetri G. Clinical management of gastrointestinal stromal tumours: before and after STI571. Hum Pathol 2002 33 : 466 77.
6. Trent JC, Beach J, Burgess MA, Papadopoulos N, Chen LL, Benjamin RS et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003 98 : 2693 9.
7. Edmonson JH, Marks RS, Buckner JC, Mahoney MR. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002 20 : 605 12.
8. Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY et al. Progression free survival in gastrointestinal stromal tumours with high and low dose imatinib: randomised trial. Lancet 2004 364 : 1127 34.
9. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumours. Recurrence patterns and prognostic factors for survival. Ann Surg 2000 231 : 51 8.
10. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B et al. Gastrointestinal stromal tumours: incidence, prevalence, clinical course, and prognostication in the pre-imatinib era - a population-based study in western Sweden. Cancer 2005 103 : 821 9.
11. Heinrich MC, Shoemaker JS, Corless CL, Hollrs D, DeMetri GD, Bentagnolli MM. Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumours (GIST's) expressing KIT (KIT+) [abstract 7]. Proceedings of the American Society of Clinical Oncology, Vol. 23. Alexandria : American Society of Clinical Oncology 2005.
12. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour. J Clin Oncol 2003 21 : 4342 9.
13. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y. Gain of function mutations of the platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumours. Gastroenterology 2003 125 : 660 67.
14. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002 3 : 655 64.
15. Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R et al. Malignant gastrointestinal stromal tumours of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001 8 : 50 59.
16. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumours. Arch Surg 2001 136 : 383 9.
17. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma. Prognostic factors to guide patient selection. Cancer 2000 88 : 66 74.
18. DeMatteo RP, Saha A, Fong Y, Jarnagin WR, Blungart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to the liver. Ann Surg 2001 234 : 540 48.
19. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD et al. Prognostic value of kit mutation type, mitotic activity, and histological subtype in gastrointestinal stromal tumours. J Clin Oncol 2002 20 : 3898 905.
20. Fletcher CMD, Berman JJ, Corless CL, Gorstein F, Lasota J, Longley BJ et al. Diagnosis of gastrointestinal stromal tumour: a consensus approach. Hum Pathol 2002 33 : 459 65.
21. Miettinen M, Lasota J. Gastrointestinal stromal tumours - definition, clinical, histological, immunohistochemical and molecular genetic features and differential diagnosis. Virchows Arch 2001 438 : 1 12.
22. Rankin C, Von Mehren M, Blanke C, Benjamin R, Fletcher CD, Bramwell V. Dose effect of imatinib in patients with metastatic GIST: Phase III Sarcoma Group Study S0033 [abstract 9005]. Proc ASCO 2004 23 : 815.
23. Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I et al. Initial and late resistance to imatinib (im) in advanced gastro-intestinal stromal tumors (gist) are predicted by different prognostic factors, an eortc-isg-agitg study. J Clin Oncol 2005 23 : 5795 804.
24. Le Cesne A, Petol D, Ray-Coquard B, Bui B, Daffaud F, Rios M. Interruption of imatinib (IM) in GIST patients with advanced disease: updated results of the prospective French Sarcoma Group randomised trial on survival and quality of life [abstract 9031]. Proceedings of the American Society of Clinical Oncology, Vol. 23. Alexandria : American Society of Clinical Oncology 2005.
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000 92 : 205 16.
26. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992 10 : 239 53.
27. Bechtold RE, Chen MY, Stanton CA, Savage PD, Levine EA. Cystic changes in hepatic and peritoneal metastasis from gastrointestinal stromal tumours treated with Gleevec. Abdom Imaging 2003 28 : 808 14.
28. Burkill GJ, Badran M, Al-Muderis O, Meirion Thomas J, Judson IR, Fisher C et al. Malignant gastrointestinal stromal tumour: distribution, imaging features, and pattern of metastatic spread. Radiology 2003 226 : 527 32.
29. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Adersson LC, Tervahartalia P, Tuveson D et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumour. N Engl J Med 2001 344 : 1052 6.
30. Antoch G, Kanja J, Bauer S, Kuehl H, Renzig-Koehler K, Schuette J. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumours. J Nucl Med 2004 45 : 357 65.
31. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM et al. CT evaluation of the response of gastrointestinal stromal tumours after Imatinib mesylate treatment: a qualitative analysis correlated with FDG PET findings. Am J Roentgenol 2004 183 : 1619 28.
32. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N et al. The role of 18F-FDG-PET in stage and early prediction of response to therapy for recurrent gastrointestinal stromal tumours. J Nucl Med 2004 45 : 17 21.
33. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003 39 : 2012 20.
34. Demetri GD, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 2002 347 : 472 80.
35. Grimison P, Goldstein D, Schneeweiss J, Murray N. Corticosteroid- responsive interstitial pneumonitis related to imatinib mesylate with successful rechallenge, and potential causative mechanisms. Intern Med J 2005 35 : 136 7.
36. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumours. J Clin Oncol 2004 22 : 3813 25.
37. Demetri GD, van Oosterom AT, Blackstein M, Garrett C, Shah M, Heinrich M et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST [abstract 4000]. Proceedings of the American Society of Clinical Oncology, Vol. 23. Alexandria : American Society of Clinical Oncology 2005.
38. Zalcberg JR, Verweijj J, Casali PG, Le Lesne A, Reichardt P, Blay JY et al. Outcome of patients with advanced gasto-intestinal stromal tumours (GIST) crossing over to a daily imatinib dose of 800 mg (HD) after progression on 400 mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG [abstract 9004]. Proceedings of the American Society of Clinical Oncology, Vol. 22. Alexandria : American Society of Clinical Oncology 2004.
39. Dileo P, Randhawa R, Vansonnenberg E, Shankar S, Desai J, Morgan JA et al. Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumour (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM) [abstract 9024]. Proceedings of the American Society of Clinical Oncology Alexandria : American Society of Clinical Oncology 2004.
40. Blay YJ, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP et al. Consensus meeting for the management of gastrointestinal stromal tumours. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005 16 : 566 78.
41. Rhim H, Golberg SN, Dodd GD, Solbiati L, Liam HK, Tonolini M et al. Essential techniques for successful radio-frequency thermal ablation of malignant hepatic tumours. Radiographics 2001 21 : S17 S35.
42. Bauer S, Hartmann T, Lang H, Antoch G, Dirsch O, Ebeling P. Imatinib may enable complete resection in previously unresectable GIST [abstract 9023]. Proceedings of the American Society of Clinical Oncology, Vol. 22. Alexandria : American Society of Clinical Oncology 2004.
43. Huges B, Yip D, Goldstein D, Waring P, Beshay V, Chong G et al. Cerebral relapse of metastatic gastrointestinal stromal tumour during treatment with imatinib mesylate: case report. BMC Cancer 2004 4.